The European Commission has approved Novo Nordisk’s new FlexTouch prefilled insulin pen. Approval has been granted for both NovoRapid (insulin aspart) and Levemir (insulin detemir), both modern insulins that are currently delivered in the FlexPen delivery device.
The Danish pharmaceutical firm says FlexTouch, its latest prefilled delivery system, offers a new insulin injection experience for users. Current insulin pens require users to inject their insulin using the force of their thumb to push the button. For some patients this can be difficult. FlexTouch has an easy touch button, which requires very little force to inject the insulin at any dose.
FlexTouch contains 300 units of insulin and doses in one-unit increments, from 1–80 units. It is compatible with NovoTwist needles, which are supplied in 5mm (32G Tip) and 8mm (30G) versions. An audible and tactile ‘click’ confirms attachment of the needle.
The launch of the FlexTouch in the EU is dependent on negotiations in individual countries.
Novo Nordisk gains EU approval for FlexTouch
Danish firm\'s latest innovation within prefilled insulin pens
You may also like
Regulatory
Five NHS trusts placed into intensive recovery programme to tackle “deep-rooted challenges”
Read moreFive underperforming NHS trusts have been identified for a new intensive recovery programme, with tailored interventions including leadership changes, structural reform and targeted investment
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more. -
You need to be a subscriber to read this article.
Click here to find out more.